Tamsulosin with solifenacin - Benign prostatic hyperplasia
You are here : Home > Formulary Search > Tamsulosin with solifenacin - Benign prostatic hyperplasia
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Documentation
Policy Statement
PAD Profile
ChemicalSubstance :
Tamsulosin with solifenacin
Indication :
Benign prostatic hyperplasia
Group Name :
Keywords :
BPH, LUTS, urinary retention
Brand Names Include :
Vesomni
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Other Indications
Below are listed other indications that Tamsulosin with solifenacin is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Benign prostatic hyperplasia.
Committee Recommendations (2)
At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.
If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.
The PCN does not recommend the use of the combination product Vesomni® (tamsulosin & solifenacin) as a treatment option for lower urinary tract symptoms in men and has assigned a BLACK traffic light status to this treatment.
Patients whose treatment was initiated by the NHS before this recommendation was made, must be reviewed by their NHS consultant but should be able to continue treatment until, the patient and their NHS consultant consider it appropriate to stop.
Patients whose treatment was initiated by the NHS before this recommendation was made, must be reviewed by their NHS consultant but should be able to continue treatment until, the patient and their NHS consultant consider it appropriate to stop.